These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

721 related articles for article (PubMed ID: 34416198)

  • 1. SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination.
    Behrens GM; Cossmann A; Stankov MV; Nehlmeier I; Kempf A; Hoffmann M; Pöhlmann S
    Lancet; 2021 Sep; 398(10305):1041-1042. PubMed ID: 34416198
    [No Abstract]   [Full Text] [Related]  

  • 2. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity.
    Bae S; Ko JH; Choi JY; Park WJ; Lim SY; Ahn JY; Song KH; Lee KH; Song YG; Chan Kim Y; Park YS; Choi WS; Jeong HW; Kim SW; Kwon KT; Kang ES; Kim AR; Jang S; Kim B; Kim SS; Jang HC; Choi JY; Kim SH; Peck KR
    Clin Microbiol Infect; 2022 Oct; 28(10):1390.e1-1390.e7. PubMed ID: 35598855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
    Niyomnaitham S; Quan Toh Z; Wongprompitak P; Jansarikit L; Srisutthisamphan K; Sapsutthipas S; Jantraphakorn Y; Mingngamsup N; Licciardi PV; Chokephaibulkit K
    Hum Vaccin Immunother; 2022 Nov; 18(6):2091865. PubMed ID: 35816053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac
    Chatsiricharoenkul S; Niyomnaitham S; Posen HJ; Toh ZQ; Licciardi PV; Wongprompitak P; Duangchinda T; Pakchotanon P; Chantima W; Chokephaibulkit K
    Front Immunol; 2022; 13():1010835. PubMed ID: 36268028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
    Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
    Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective Duration of ChAdOx1 and BNT162b2 Vaccines Against SARS-CoV-2 Infection.
    Alfaleh A; Alkattan A; Alzaher A; Radwan N; Mahmoud N; Alageel A; Alhabib D; Alsalameen E; Sagor K; Haji A; Alfaifi A; Alabdulkareem K; Ibrahim M
    Clin Drug Investig; 2022 Oct; 42(10):799-806. PubMed ID: 36040662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
    Trigueros M; Pradenas E; Palacín D; Muñoz-López F; Ávila-Nieto C; Trinité B; Bonet-Simó JM; Isnard M; Moreno N; Marfil S; Rovirosa C; Puig T; Grau E; Chamorro A; Martinez A; Toledo R; Font M; Ara J; Carrillo J; Mateu L; Blanco J; Clotet B; Prat N; Massanella M;
    Age Ageing; 2022 May; 51(5):. PubMed ID: 35595256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
    Vogel E; Kocher K; Priller A; Cheng CC; Steininger P; Liao BH; Körber N; Willmann A; Irrgang P; Held J; Moosmann C; Schmidt V; Beileke S; Wytopil M; Heringer S; Bauer T; Brockhoff R; Jeske S; Mijocevic H; Christa C; Salmanton-García J; Tinnefeld K; Bogdan C; Yazici S; Knolle P; Cornely OA; Überla K; Protzer U; Schober K; Tenbusch M
    EBioMedicine; 2022 Nov; 85():104294. PubMed ID: 36206622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postvaccination infections among staff of a tertiary care hospital after vaccination with severe acute respiratory syndrome coronavirus 2 vector and mRNA-based vaccines.
    Brunner-Ziegler S; Spath T; Kornek G; König F; Parschalk B; Schnetzinger M; Straßl RP; Savic R; Foit A; Resch H; Thalhammer F
    Clin Microbiol Infect; 2022 Apr; 28(4):596-601. PubMed ID: 34915073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
    Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S
    Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2.
    Hermosilla E; Coma E; Xie J; Feng S; Cabezas C; Méndez-Boo L; Fina F; Ballo E; Martínez M; Medina-Peralta M; Argimon JM; Prieto-Alhambra D
    Nat Commun; 2022 Mar; 13(1):1639. PubMed ID: 35322045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralisation of the SARS-CoV-2 Delta variant sub-lineages AY.4.2 and B.1.617.2 with the mutation E484K by Comirnaty (BNT162b2 mRNA) vaccine-elicited sera, Denmark, 1 to 26 November 2021.
    Lassaunière R; Polacek C; Fonager J; Bennedbæk M; Boding L; Rasmussen M; Fomsgaard A
    Euro Surveill; 2021 Dec; 26(49):. PubMed ID: 34886943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
    Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
    BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccination with BNT162b2 and ChAdOx1 vaccines has the potential to induce nasal neutralizing antibodies.
    Declercq J; Tobback E; Vanhee S; De Ruyck N; Gerlo S; Gevaert P; Vandekerckhove L
    Allergy; 2022 Jan; 77(1):304-307. PubMed ID: 34543444
    [No Abstract]   [Full Text] [Related]  

  • 20. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
    Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
    Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.